Today: 3 June 2026
Browse Category

Pharmaceuticals 8 October 2025 - 21 October 2025

SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

Spero shares closed at $2.29 on Oct. 20, 2025, up 3.6%, after reporting Phase 3 trial results showing oral tebipenem HBr matched IV imipenem in overall success (58.5% vs 60.2%) at IDWeek. The stock has surged over 120% year-to-date, trading between $0.51 and $3.22. GSK plans an FDA submission in Q4. Analyst 12-month targets average $5, but ratings remain mixed following a recent Zacks downgrade.
21 October 2025
···
AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

Recursion Pharma Stock Soars 16% on AI Buzz and Big Pharma Deals – Can RXRX Keep Climbing?

Recursion Pharmaceuticals shares jumped over 16% to $6.80 intraday on Oct. 20, capping a volatile month that saw a 44% gain and heavy trading volume. CEO Chris Gibson sold 100,000 shares on Oct. 10 for about $604,000, drawing analyst scrutiny. The company reported a Q2 net loss of $171.9 million on $19.2 million revenue. Recursion recently acquired Exscientia in a $630 million all-stock deal.
20 October 2025
··
Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer shares surged 15% from $23.6 to $27.2 after announcing a Medicaid pricing deal with the Trump administration and agreeing to buy obesity drug developer Metsera for up to $7.3 billion. Q2 revenue rose 10% to $14.7 billion, beating estimates. Pfizer trimmed its dividend but still yields 6–7%. Analysts raised price targets to $29–30, citing the pricing pact and new drug prospects.
19 October 2025
·
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics shares surged over 150% on Oct. 17, 2025, after announcing a collaboration and license deal with Chugai Pharmaceutical worth up to $1.085 billion. The company also raised $60.3 million in PIPE financing, stating it now has funding into 2028. Trading volume spiked to 70 million shares, up from a 300,000 average. Analyst opinions remain split on the stock’s outlook.
18 October 2025
···
Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences Stock Soars on Patent Win and HIV Breakthroughs – Will the Rally Continue?

Gilead Sciences stock jumped over 4% on Oct. 17, 2025, closing at $122.81 and hitting a new 52-week high. The surge follows a patent settlement extending exclusivity for Biktarvy until 2036 and FDA approval of Yeztugo, a new HIV prevention shot. Gilead’s market cap stands near $150 billion after a 47% year-to-date gain. Analysts remain bullish but note concerns over U.S. drug pricing pressures.
18 October 2025
···
Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom

Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom

Hims & Hers Health launched a menopause and perimenopause care program on its Hers platform Oct. 15, triggering a one-day stock surge of up to 16%. Shares quickly reversed, falling 11% to around $52–53 by Oct. 17. The company aims for $1 billion annual revenue in women’s health by 2026. Analysts remain divided, citing high valuation and volatile trading despite rapid revenue growth.
17 October 2025
·
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics shares surged nearly 190% to $1.37 on Oct. 17, 2025, after announcing a pharma partnership with Chugai Pharmaceutical worth up to $1.085 billion. The deal includes $10 million upfront, development and sales milestones, and potential royalties. Rani also raised $60.3 million in a private placement, extending its cash runway into 2028. Trading volume spiked to several times the daily average.
17 October 2025
···
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Surges on Obesity Drug Boom and Alzheimer’s Breakthroughs – Is $1,000 Next?

Eli Lilly shares hit a record $832 intraday on Oct. 1, fueled by demand for its obesity drugs and Alzheimer’s advances, before slipping 4% after Donald Trump pledged to cut weight-loss drug prices. Lilly’s Mounjaro and ZepBound now hold 57% of U.S. GLP-1 prescriptions, outpacing Novo Nordisk. First-half 2025 revenue jumped about 40% year-on-year. Most analysts remain bullish, despite valuation and policy concerns.
17 October 2025
··
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s Weight-Loss Crown at Risk? NVO Stock Slumps Amid Surprise Deals – What’s Next

Novo Nordisk shares fell 6.7% in Copenhagen on Oct. 17, 2025, and U.S. pre-market quotes pointed to a further 4.8% drop. The stock has lost over 40% year-to-date, erasing hundreds of billions in value. Recent acquisitions and job cuts have not reversed investor caution, as competition from Eli Lilly intensifies and analysts warn of more profit downgrades.
17 October 2025
··
Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis Precision Medicines shares jumped 180% to $162 on Oct. 16 after its lead drug, ulixacaltamide, met all key endpoints in two Phase 3 trials for essential tremor. The rally added nearly $3 billion to the company’s market cap. Praxis announced a $525 million public offering to fund commercialization and pipeline expansion. Analyst price targets surged, with several now above $250.
17 October 2025
··
Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

SCNX shares jumped over 30% in early trading Oct. 16 after Scienture announced Arbli, the first FDA-approved ready-to-use liquid losartan, is now available through major wholesalers. The stock hit an intraday high of $1.12 before trading near $0.71 by mid-day. Scienture recently secured a major rebate deal to drive Arbli’s adoption. Analysts remain cautious, citing weak financials and high volatility.
16 October 2025
··
Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Adaptimmune Therapeutics shares surged 42% on October 8, 2025, after nearly doubling intraday on September 19, despite no major news and record trading volumes. The company sold its key T-cell therapy programs, including Tecelra, to US WorldMeds for $55 million upfront to pay off debt and avoid insolvency. Q2 net loss reached $30.3 million, with cash reserves at $26 million by mid-year. Analysts remain bearish, with no major buy ratings.
16 October 2025
··
Menopause Launch Sends Hims & Hers (HIMS) Stock Soaring – What’s Next?

Menopause Launch Sends Hims & Hers (HIMS) Stock Soaring – What’s Next?

Hims & Hers shares jumped 16% on Oct. 15 after launching a menopause care program, trading near $62.80 on Oct. 16, up 7% for the day. The stock has more than doubled in 2025, far outpacing rivals like Teladoc. Regulatory scrutiny from the FDA and FTC triggered brief sell-offs in September. Analyst sentiment remains cautious, with most price targets in the high $30s despite recent gains.
16 October 2025
··
AstraZeneca (AZN) Stock Skyrockets: $50B U.S. Gamble, Trump Pricing Deal & Analyst Forecasts

AstraZeneca (AZN) Stock Skyrockets: $50B U.S. Gamble, Trump Pricing Deal & Analyst Forecasts

AstraZeneca shares traded near £127.82 ($85 ADR) on Oct. 10, 2025, close to a 52-week high after a U.S. NYSE listing and a $4.5 billion Virginia plant announcement. Market cap stands at $264 billion, with 2024 revenue of $54.1 billion, up 18%. The company agreed to provide U.S. Medicaid with its lowest global drug prices. Shares have rallied over 10% since late September.
11 October 2025
···
Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics shares surged over 30% to nearly $89 on October 10, 2025, after reports that Johnson & Johnson is in talks to acquire the company. Trading was briefly halted due to volatility. The company, valued at about $5.4 billion, recently announced positive trial results for its lead drugs and secured major partnerships with J&J and Takeda.
11 October 2025
·····
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk will acquire Akero Therapeutics for up to $5.2 billion, paying $54 per share in cash plus a potential $6 per share if Akero’s lead drug wins U.S. approval by 2031. Akero’s efruxifermin, in Phase 3 trials for fatty liver disease, has shown reversal of liver fibrosis in mid-stage studies. Akero shares jumped 19% on the news, while Novo shares were little changed. The deal is expected to close by year-end.
9 October 2025
··
90% Plunge to 1000% Upside? Acurx Pharmaceuticals (ACXP) Stock Sees EMA Boost & Bold Analyst Predictions

90% Plunge to 1000% Upside? Acurx Pharmaceuticals (ACXP) Stock Sees EMA Boost & Bold Analyst Predictions

Acurx Pharmaceuticals shares have fallen about 90% from their 52-week high, trading near $4.30 after a 1-for-20 reverse split in August. The stock briefly rallied in late September after the European Medicines Agency issued a positive opinion on its pediatric plan for ibezapolstat. Acurx remains pre-revenue with $6.1 million in cash at Q2’s end and faces additional funding needs for Phase 3 trials.
8 October 2025
·
1 … 37 38 39 40 41

Latest articles

Amazon Gets June Prime Day Announcement, Stock Falls

Amazon Gets June Prime Day Announcement, Stock Falls

3 June 2026
Amazon shares slid 1.81% to $256.52 even as it set June 23-26 for Prime Day, giving investors an early look at retail momentum before Q2 ends; despite strong AWS growth and rising net sales, free cash flow fell as AI investments surged, leaving investors cautious about whether Prime Day’s grocery push and earlier timing will boost margins or just shift demand.
Apple Shares Reach New High as AI Decision Looms

Apple Shares Reach New High as AI Decision Looms

3 June 2026
Apple surged 2.9% to a record $315.20, adding $598 billion in May, as investors bet next week’s WWDC will reveal major AI advances; with high expectations and a $100 billion buyback, the stock’s rally leaves little room for disappointment on Siri upgrades, AI features, or rising memory-chip costs.
GameStop Reports Record Profit, Plans $2 Billion Buyback as eBay Concerns Surface

GameStop Reports Record Profit, Plans $2 Billion Buyback as eBay Concerns Surface

3 June 2026
GameStop posted record Q1 net income of $389.6 million, fueled by collectibles now making up 41.8% of sales, and unveiled a new $2 billion share buyback; shares jumped 7.4% in after-hours trading as investors reacted to the earnings beat and capital return plan, even as the company warned future results hinge on collectibles demand and market risks.
Ulta Beauty Raises Outlook, Shares Jump on Steady Beauty Demand

Ulta Beauty Raises Outlook, Shares Jump on Steady Beauty Demand

2 June 2026
Ulta Beauty shares jumped 7% in extended trading after quarterly earnings and comparable sales beat estimates, prompting the company to raise its full-year profit forecast as shoppers spent more on higher-priced beauty products; net income climbed to $340.5 million and gross margin improved to 40.1%, though Ulta warned inflation and macro pressures could impact future spending.
GitLab shares rise on stronger AI outlook, 350 layoffs announced

GitLab shares rise on stronger AI outlook, 350 layoffs announced

2 June 2026
GitLab shares jumped 7% in late trading after beating Wall Street sales estimates and raising its annual forecast, as investors weigh whether its AI-powered Duo Agent Platform can boost growth amid a 14% workforce cut and continued competition from Microsoft’s GitHub.
Go toTop